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Abstract
Fungi cause diverse, serious socio-economic problems, including biodeterioration of valuable products and materials that spawns
a biocides industry worth ~$11 billion globally. To help combat environmental fungi that commonly colonise material products,
this study tested the hypothesis that combination of an approved fungicide with diverse agents approved by the FDA (Food and
Drug Administration) could reveal potent combinatorial activities with promise for fungicidal applications. The strategy to use
approved compounds lowers potential development risks for any effective combinations. A high-throughput assay of 1280 FDA-
approved compounds was conducted to find those that potentiate the effect of iodopropynyl-butyl-carbamate (IPBC) on the
growth of Trichoderma virens; IPBC is one of the two most widely used Biocidal Products Regulations–approved fungicides.
From this library, 34 compounds in combination with IPBC strongly inhibited fungal growth. Low-cost compounds that gave the
most effective growth inhibition were tested against other environmental fungi that are standard biomarkers for resistance of
synthetic materials to fungal colonisation. Trifluoperazine (TFZ) in combination with IPBC enhanced growth inhibition of three
of the five test fungi. The antifungal hexetidine (HEX) potentiated IPBC action against two of the test organisms. Testable
hypotheses on the mechanisms of these combinatorial actions are discussed. Neither IPBC + TFZ nor IPBC + HEX exhibited a
combinatorial effect against mammalian cells. These combinations retained strong fungal growth inhibition properties after
incorporation to a polymer matrix (alginate) with potential for fungicide delivery. The study reveals the potential of such
approved compounds for novel combinatorial applications in the control of fungal environmental opportunists.
Key points
• Search with an approved fungicide to find new fungicidal synergies in drug libraries.
• New combinations inhibit growth of key environmental fungi on different matrices.
• The approach enables a more rapid response to demand for new biocides.
Keywords Fungicide . Biodeterioration . Biodegradation . Aspergillus brasiliensis . Penicillium funiculosum . Chaetomium
globosum . Aureobasidium pullulans
Introduction
The fungi include major pathogens of humans, plants and
livestock, food spoilage organisms, and organisms causing
deterioration of synthetic products and materials (Fisher
et al. 2020; Meyer et al. 2016). Therefore, they have
substantial economic and societal importance. Fungal that col-
onise products and materials and may cause their deterioration
are characterised by high rates of spore dissemination to the
surrounding environment, ability to colonise diverse sub-
strates and, depending on the species, the potential for myco-
toxin production and pathogenicity (Pitkaranta et al. 2011).
Furthermore, approximately 10% of people worldwide suffer
allergies to environmental fungi (Chakravarty and Kovar
2013; Robbins et al. 2000).
Biocides are important for preventing biodeterioration of a
variety of material products including plastics, paints and
coatings, metalworking fluids, textiles, building materials,
wood, and cosmetics. All of these are susceptible to fungal
colonisation. However, the actions of biocides against fungi
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are less well characterised than against bacteria, and also com-
pared with antifungal drugs that are used for treating disease.
In general, fungi are more resistant to biocides than
nonsporulating Gram-positive bacteria, but can be more sen-
sitive than Gram negative bacteria (McDonnell and Russell
1999). Halogen compounds are a key biocide class, followed
bymetallic compounds and organosulfurs. However, there are
growing environmental and regulatory concerns over the uses
of metallic or halogenated compounds containing bromine
and chlorine, and stringent regulations regarding their use
are likely to accentuate the need for alternative biocide treat-
ments (https://echa.europa.eu/legislation). Developing new
biocides involves high costs and takes time given the
regulatory hurdles, which does not encourage such
investment. An alternative route for the industry could be
development of new blends of existing biocides. For
example, the combination of iodopropynyl-butyl-carbamate
(IPBC) and 2-n-octyl-4-isothiazolin-3-ones (OIT) is used in
current commercial preservatives, for water-borne dry film
interior coatings. IPBC is a water-soluble, halogenated and
unsaturated carbamate derivative that exhibits strong fungicid-
al activity. It is a Biocidal Products Regulations (BPR)–ap-
proved fungicide that has been in use for many years as a
wood and paint preservative. IPBC has also found applica-
tions in the cosmetics industry (Maier et al. 2009; Steinberg
2002) and has been approved by the Food and Drug
Administration (FDA) as an adhesive component for use in
food packaging and storage. However, several cases of aller-
gic contact dermatitis have been related to IPBC use
(Badreshia and Marks Jr 2002; Vanhoutte et al. 2019).
In this study, it was hypothesised that a much more diverse
range of agents could have potential use against environmen-
tal fungi in combination with IPBC. Such agents were
screened for in a FDA-approved compound library. The re-
purposing of existing, approved drugs for alternative uses has
emerged as a key approach for facilitating therapeutic drug
development (Holbrook et al. 2017; Robbins et al. 2015;
Roemer and Krysan 2014; Spitzer et al. 2011; Vallieres et al.
2020b). Here, this strategy was adapted for biocide discovery.
The study reports new combinations that effectively and se-
lectively target fungi of the ASTM G21 group—the standard
used by the industry for determining resistance of synthetic
polymeric materials to fungi (www.astm.org/cgi-bin/resolver.
cgi?G21)—including after incorporation to a polymer matrix,
supporting the potential for applications.
Methods
Strains, culture, and maintenance
Fungal strains used in this study were the moulds
Aspergillus brasiliensis ATCC 9642, Penicillium
funiculosum ATCC 11797, Chaetomium globosum
ATCC 6205, Aureobasidium pullulans ATCC 15233,
and Trichoderma virens ATCC 9645 from the ASTM
G21 group (www.astm.org/cgi-bin/resolver.cgi?G21).
The fungi were inoculated from spore stocks kept at −
80 °C (in potato dextrose broth (PDB; Sigma, St Louis,
MO, USA) and 20% glycerol) onto potato dextrose agar
(PDA; Oxoid, Basingstoke, UK) and cultured for 7 days
at room temperature. Using a sterile cotton bud, spores
were transferred from these starter plates to new PDA
plates. Starter plates were kept at 4 °C for a maximum
of 3 weeks. Fungi on the new plates were grown for 7
days at room temperature before spores were harvested in
PDB and filtered through a 40-μm cell strainer for exper-
imental use. The collected spores were checked for purity
by microscopy and counted using a hemocytometer.
Growth assays (below) were performed in PDB at 30 °C.
High-throughput screening
Compounds of the Prestwick Chemical Library (PL)
(Prestwick Chemical, Illkirch-Graffenstaden, France) were
used at a final concentration of 100 μM in the presence or
absence of 200 ng ml−1 IPBC (Sigma). Screens were per-
formed using T. virens spores inoculated from 7-day PDA
plates to PDB broth adjusted to a final concentration of
15,000 spores ml−1. Aliquots (100 μl) of the spore suspension
in PDB, plus chemical supplements as above, were transferred
to 96-well plates (Greiner Bio-One, Stonehouse, UK) and cul-
tured for 72 h at 30 °C with OD600 measured at 40 h and 72 h
in a BioTek EL800 microplate spectrophotometer. OD600 was
expressed as percentage of growth relative to control growth
(i.e., without added IPBC or PL compound). Effect strength
((% growth with PL compound) minus (% growth with PL
compound + IPBC)) was calculated for each combination;
screen hits were considered those agents showing an effect
strength >50.
One thousand compounds from the University of
Nottingham Managed Chemical Compound Collection
(NMCCC) were also tested in combination with IPBC
against the yeast Saccharomyces cerevisiae BY4743.
S. cerevisiae was grown overnight in YPD broth (2%
peptone (Oxoid), 1% yeast extract (Oxoid), 2% D-glu-
cose), diluted to OD600 ~0.5 and cultured for a further
4 h in fresh medium before being diluted again to
OD600 ~0.1 as described previously (Moreno-Martinez
et al. 2015). Aliquots (150 μl) of the diluted culture plus
any chemical supplements (IPBC, 0.5 μg/ml; NMCCC
compounds, 133 μM) were transferred to 96-well plates.
OD600 was measured at 20 h using a BioTek EL800 mi-
croplate spectrophotometer and effect strength calculated
as above.
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Growth inhibition and cell toxicity assays for selected
combinations of agents
Growth inhibition assays in PDB broth: the assays were per-
formed as above with OD600 measured at 40 h. Combinatorial
effect strength was calculated as follows: (% inhibition with
IPBC + PL compound) minus (% inhibition with IPBC alone
+ % inhibition with PL compound alone). Combinations of
interest were considered those with a combinatorial effect
strength > 20.
Growth inhibition assays on coated coverslips: round cov-
er glasses (13 mm diameter, thickness No. 1; VWR, Radnor,
PA) were dip coated in 0.25% (w/v) sodium alginate, supple-
mented with inhibitors where indicated, and air-dried for an
hour. A suspension of T. virens spores (106 spores ml−1 from
7-day old PDA plates, suspended in nutrient salts solution
[0.5% peptone (Oxoid), 0.3% yeast extract (Oxoid), 0.5%
sodium chloride (Sigma), pH 6.8]) was sprayed onto the coat-
ed cover glasses and these were then placed spore-side up-
wards onto water agar [sterile distilled water, 2% (w/v) agar]
in 12-well plates (Greiner, Kremsmünster, Österreich). Plates
were incubated at 30 °C for 14 days before microscopic im-
ages were captured to assess growth of T. virens on the coated
cover glasses.
Cell toxicity assays: human cells (TE671, rhabdomyosar-
coma RD cell line) were cultured and toxicity to the cells was
assayed using the CCK-8 reagent (Sigma) as described previ-
ously (Moreno-Martinez et al. 2015).
Results
Development of new compound combinations with
BPR-approved IPBC, for fungal inhibition
The study was performed with the five fungi of the ASTM
G21 group (A. brasiliensis, A. pullulans, P. funiculosum,
C. globosum, T. virens), as these are the industry standard
for determining resistance of synthetic polymeric materials
to environmental fungi. This group was originally selected
by the ASTM based on their affinities for using plasticizers,
cellulose, lubricants, stabilisers, and colorants as growth sub-
strates. A screen was performed against T. virens, with the
Prestwick chemical library (PL), comprising 1280 FDA-
approved compounds, in the absence and presence of a low
concentration of the BPR-approved agent IPBC (i.e., 200
ng/ml, which produces less than 10% reduction of growth
yield). T. virens was used for these screens as it gave the best
reproducibility in growth assays and hence confidence in
identifying the screen hits. A relatively low spore density
(15,000 spores ml−1) was used to maximise sensitivity of de-
tection of milder drug effects. Library compounds were sup-
plied at 100 μM, the maximum concentration attainable while
ensuring that the added volumes of the stock solutions (in
dimethyl sulfoxide, DMSO) did not exceed 2% of the final
volumes. Measurements of growth inhibition by the PL agents
alone or in combination with IPBCwere taken at two different
time points, 40 h and 72 h, which correspond to early and later
stationary growth phases and were shown previously to be
suitable for detecting strong combinatorial effects (O’Brien
et al. 2019). At 100 μM, ~90% of PL agents had minimal
growth effects when supplied alone (i.e., less than 20% reduc-
tion of growth yield) (Fig. 1A, Supplemental Table S1). Forty-
nine PL compounds gave more than 75% reduction of the
T. virens growth yield after 72 h; these included 26 known
fungicides including 16 azoles, and 3 antiseptics
(Supplemental Table S1). When IPBC was included, effect
strengths were calculated in order to identify combinations
of potential interest, selected here as those that showed an
effect strength >50 (i.e., where the difference between %
growth with PL compound alone and the combination was
>50). At 40 h, 27 combinations exhibited an effect strength
>50, but only 10 of these retained this effect at 72 h (Fig. 1B,
Table 1, Supplemental Table S1). At the later time point, a
total of 17 combinations showed an effect strength >50 (Fig.
1B, Table 1, Supplemental Table S1). Of these, the seven that
did not appear as potential hit combinations at 40 h included
PL compounds which were effective on their own at that time
point with a reduction of growth >55%. The most promising
library compounds were selected for further tests based on
three criteria: efficacy of T. virens growth inhibition in com-
bination with IPBC at t 72 h; known modes of action (e.g.,
where several compounds had similar, known modes of
action, certain examples were selected; Table 1); low relative
cost (< £50 per gram; Sigma; Table 1). These were thiorida-
zine hydrochloride (TZ), flunarizine dihydrochloride (FZ), tri-
fluoperazine dihydrochloride (TFZ), and prochlorperazine
dimaleate (PZ). The known antifungal hexetidine (HEX),
which showed a promising effect in combination with IPBC
at t 40 h, was also selected as hexetidine additionally has
biocidal approval (Table 1).
Spectrum of activity against environmental fungi of
concern to the biocides industry
To assess the spectrum of activity of the most promising com-
binations selected from the screen (Table 1), each of these was
tested against five environmental fungi from the ASTM G21
group described above. Agents were supplied at sub-
inhibitory concentrations (determined in preliminary assays)
alone or in combination and growth was measured at 40 h. As
agents in some instances showed an effect on their own, here
the combinatorial effect strength was calculated slightly dif-
ferently than effect strength above, i.e., (% inhibition with
IPBC + PL agent) minus (% inhibition with IPBC alone + %
inhibition with PL agent alone). The combinatorial effect
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strength of TFZ with IPBC was >25 against three environ-
mental fungi (A. pullulans, T. virens, and P. funiculosum)
(Fig. 2). HEX + IPBC showed a strong (>50) combinatorial
effect against A. pullulans and T. virens (Fig. 2). Although
other test fungi like A. brasiliensis did not score such an effect
with this combination, it should be noted that A. brasiliensis is
much more sensitive to either of these agents alone. Complete
inhibition of A. brasiliensis growth occurred at concentrations
(MICs 250 ng ml−1 and 250 μM for IPBC and HEX,
respectively; not shown) that corresponded approximately to
the sub-inhibitory concentrations used for T. virens (200 ng
ml−1 and 200 μM, respectively). Therefore, application of
combination dosages needed to control growth of the more
resistant fungi (e.g., T. virens) could also inhibit more sensi-
tive fungi (e.g., A. brasiliensis) regardless of a combinatorial
effect.
To assess specificity of the combinations for the fungi, the
effects of the most promising combinations IPBC + TFZ and
Table 1 Hits from high-throughput chemical screening for agents that potentiate T. virens growth inhibition by IPBC at t 72 h.
Effect strengtha Targetb Cost in £/g (Sigma reference) Selected for further experimentsc
t 40 h t 72 h




Perphenazine 54.8 110.5 Dopaminergic receptors 30
(P6402-5G)
No
Similar target as PZ, TZ, and TFZ
Flunarizine dihydrochloride 90.1 110.4 Ca2+ channel 34
(F8257-10G)
Yes




Similar target as PZ, TZ, and TFZ
Prochlorperazine dimaleate 27.8 105.0 Dopaminergic receptors 10
(P9178-5G)
Yes








Halofantrine hydrochloride 11.8 88.2 Not listed 9460
(H9414-50MG)
(Yes)
Fluphenazine dihydrochloride 41.1 88.0 Dopaminergic receptors 41
(F4765-5G)
No
Similar target as PZ, TZ, and TFZ




Thioridazine hydrochloride 50.0 80.0 Dopaminergic receptors 9
(T9025-25G)
Yes
Methiothepin maleate 41.5 73.6 Serotoninergic 5-HT receptors Not available No
Expense




Suloctidil 54.8 63.5 Not listed Not available No
Expense
Trifluoperazine dihydrochloride 15.6 59.9 Dopaminergic receptors 12
(T8516-10G)
Yes








Hexetidine 76.6 27.2 Membrane 12
(259187-10G)
Yes
a Effect strength ≥50 shown in bold
b Information from Prestwick Library Data Sheet
c Four compounds from the screen hits at 72 h were selected for further experiments based on low relative cost (< £50 per gram) and target (e.g., 6
compounds in the table are known to target dopaminergic receptors so only 3 of these were selected as representative for that class of inhibitors). As the
approved biocide hexetidine showed potential at t 40 h, the agent was also selected. Halofantrine was selected for an experiment described in Fig. 4
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IPBC + HEX on human cell viability were tested. TFZ and
HEX did not significantly potentiate the effect of IPBC
against the human cell line, suggesting that the combinatorial
effects were specific to the fungi (Fig. 3).
Ten of the 17 compounds highlighted earlier were relatively
expensive and therefore might not be attractive as biocides
(Table 1). These included halofantrine; halofantrine + IPBC
had an effect strength of 88. Halofantrine is related to the cheap
antimalarial drug quinine. Therefore, both antimalarials were
tested in combination with IPBC, against the five ASTM G21
fungi (Fig. 4). Quinine potentiated the effect of IPBC against
three of these environmental fungi while halofantrine potentiat-
ed IPBC action against two of them (A. pullulans and T. virens).
Activity against T. virens within alginate material
For potential applications, ideally biocide combinations
would retain their efficacy in or on products to which they
could be incorporated, e.g., polymers, thermoplastics, coat-
ings, and construction materials. Here, as a proof of principle,
the most promising fungicidal combinations, IPBC + TFZ and
IPBC + HEX (IPBC + quinine was not assayed as quinine is
not a PL compound), were incorporated in a biodegradable
alginate polymer matrix that has shown potential as an anti-
fungal and fungicide delivery system (Singh et al. 2009a;
Singh et al. 2009b; Spadari et al. 2017). Agents were incor-
porated in 0.25% sodium alginate alone or in combination;
alginate on its own did not exert fungal growth inhibition
(Supplemental Fig. S1). Mixtures were used to dip-coat cover
glasses before assessing effects on T. virens growth. Both the
combinations IPBC + TFZ and IPBC + HEX retained strong
Fig. 1 High-throughput chemical
screening for agents that
potentiate fungal growth
inhibition by IPBC. (A) The
scatterplots show the normalised
growth yield (OD600) of T. virens
for each PL compound in the
absence (x axis) and presence (y
axis) of IPBC, at 40 h and 72 h.
The data are means from
duplicate screens. (B) Effect
strengths of the 1280
combinations; those that showed
an effect strength >50 at 40 h are
coloured in pink, at 72 h in blue
(in A and B) and at both time
points in orange (panel on the
right ). Agents selected for further




hexetidine. The full dataset is in
Supplemental Table S1
Fig. 2 Library compound chemical interactions with IPBC in several
environmental fungi. The colour gradient relates to the combinatorial
effect strength for each combination, determined after 40 h growth of
the fungus indicated. Combinatorial effect strength was calculated as
described in the “Methods”. Data are means from at least three
independent experiments. TZ, thioridazine, FZ, flunarizine, TFZ,
trifluoperazine, PZ, prochlorperazine, HEX, hexetidine
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inhibition of T. virens growth after incorporation within the
alginate gel, when compared to the effects of the single agents
alone (Fig. 5). There was some variation between certain in-
dependent experiments, but there was no sign of significant
growth in 7 of the 8 experiments where the agents were sup-
plied as combinations. As the experiments aimed to establish
whether combination effects of the two agents were retained
when in the alginate gel, and not to optimise the matrix, drug
release properties from the gel were not evaluated. However,
the data show that properties of combinatorial fungal inhibi-
tion were retained in the dip-coated alginate matrix, indicating
that both drugs were available in sufficient concentrations
over the time periods of the experiments to prevent fungal
growth.
Discussion
This study’s premise was that combination of the BPR-
approved compound IPBC, with different FDA-approved
agents may facilitate development of novel biocide combina-
tions for combatting environmental fungi. These are the fungi
that colonise commercial products and materials, causing their
contamination and potential deterioration. Supporting the
study’s hypothesis, several novel combinations were identi-
fied where antifungal efficacies of the individual agents were
strongly potentiated. As biocides are typically used on or in
products, their efficacy should be resilient in these applica-
tions, e.g., after incorporation to a polymer material. As proof
of principle, an alginate polymer matrix was used to assess
that potential for the combinations identified in this work.
Alginate is a natural polymer that has been explored in anti-
fungal and fungicide delivery systems, including with the car-
bamate thiram, due to its low toxicity, biodegradability, and
low cost (Singh et al. 2009a; Singh et al. 2009b; Spadari et al.
2017). Recently, polymeric materials that prevent fungal at-
tachment and colonisation passively (i.e., without killing the
organism), including by A. brasiliensis, have been discovered
(Vallieres et al. 2020a). Incorporation of the combinations to
those polymers could potentially offer added protection from
harmful fungi.
A high-throughput chemical library screening strategy
(with the Prestwick library) proved effective here for identify-
ing agents that strongly inhibit fungal growth when combined
with IPBC. Among potential combinations of interest (based
on criteria like relative efficacy, low cost, and mode of action),
subsequent focus was mainly on trifluoperazine + IPBC and
hexetidine + IPBC. The combinations were effective against
at least two of the five environmental fungi from the industry-
standard ASTM G21 group; their effect was greater than ex-
pected from the individual effects. As the combinations of
interest were not effective against all of the fungi, this implies
that, in potential applications, selection of appropriate treat-
ments would need to be tailored to particular identified fungi.
Moreover, the combinatorial effect observed against the fungi
was not observed against human cells suggesting a fungal
specificity. Criteria such as relative efficacy and low cost were
not exhaustive as the study was primarily concerned with
proof of principle. Other criteria like environmental stability
Fig. 3 Trifluoperazine and
hexetidine do not potentiate the
effect of IPBC in a human cell
line. Cells were incubated for 24 h
in the presence of the compounds
alone or in combination. Cell
viability was then measured using
a CCK-8 kit. The values are
means ± SEM from three replicate
experiments. The combinatorial
effect strength for both
combinations is <12. There were
no significant differences
between the conditions according
to multiple comparisons (Tukey’s
test) by one-way ANOVA
Fig. 4 Halofantrine and quinine interactions with IPBC against the
ASTM G21 fungi. After 40 h growth of the five indicated fungi,
combinatorial effect strength was calculated as described in the
“Methods” for the combinations halofantrine + IPBC and quinine +
IPBC. The values are means ± SEM from at least three independent
experiments
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would need to be evaluated to progress new biocide combina-
tions to final application. Mode of action was also considered.
Six of the 17 agents with an effect strength >50 after 72 h with
IPBC are known to target dopaminergic receptors in humans,
which contributed to us ruling out several of these. Ten of the
17 were not considered attractive as biocides as they were
relatively expensive; among these, the antimalarial
halofantrine is related to the cheap drug quinine, which was
found to potentiate the effect of IPBC against three of the
environmental fungi. This highlights the added possibility
from the present study of considering hits that may be non-
ideal, for different reasons, as providing chemical signatures
for seeking related alternatives that may not have the same
drawbacks, thus greatly expanding the potential array of
chemical hits arising from this approach. This also shows that
the present, high-throughput PL screen was by no means ex-
haustive. Also, only FDA-approved compounds were consid-
ered. A key advantage is that information on toxicology and
pharmacokinetics from preclinical and clinical trials is already
available, lowering regulatory barriers, development time, and
cost. Therefore, the re-purposing of such agents for alternative
uses has emerged as one strategy to facilitate development of
antifungal therapeutic treatments (Holbrook et al. 2017;
Robbins et al. 2015; Roemer and Krysan 2014; Spitzer et al.
2011).
Novel biocide combinations could also be identified by
screening other ranges of compounds with IPBC. Recently,
copper, which has BPR approval for some applications, and
aminoglycoside antibiotics have both been found to act syn-
ergistically with fungicide carbamates such as thiram and zi-
ram (Vallieres et al. 2018). As IPBC is also a carbamate, this
suggests further chemistries with which IPBC could potential-
ly be combined effectively. Synergy between IPBC and
epoxy-amine oligomers from terpenes was observed against
T. virens growth (O’Brien et al. 2019). To corroborate the
wider potential for detecting novel combinations of interest
with IPBC, an additional screen has been performed with
1000 compounds encompassing broad chemical space from
the University of Nottingham Managed Chemical Compound
Collection (NMCCC; which comprises >100,000 compounds
in total). Encouragingly this additional screen, using the yeast
S. cerevisiae, revealed four further compounds showing a
combinatorial effect with IPBC (Supplemental Fig. S2;
Supplemental Table S1).
As mentioned above, six of the 17 combinatorial effects
observed at 72 h fungal growth involved a dopaminergic drug.
Chemogenomic screens using yeast revealed that strains de-
leted in aromatic amino acid biosynthetic genes were hyper-
sensitive to dopaminergic compounds (Ericson et al. 2008).
Given that aromatic amino acids are precursors to dopamine,
they considered that the sensitivity might reflect a blockage of
aromatic amino acid uptake in yeast, requiring yeast to acti-
vate the corresponding biosynthetic pathways. Dopaminergic
drugs like trifluoperazine are also known to inhibit the essen-
tial calcium-binding protein calmodulin (Butts et al. 2013;
Prozialeck andWeiss 1982) and to perturb membrane, vesicle
trafficking, and lipid biosynthesis pathways (Spitzer et al.
2011). Trifluoperazine has a synergistic action with flucona-
zole against several fungal pathogens (Spitzer et al. 2011).
Membrane disruption caused by this agent may perturb ergos-
terol metabolism and therefore potentially increase suscepti-
bility to accumulation of ergosterol intermediates, disturb flu-
conazole export by drug efflux pumps, and/or impair import
of exogenous ergosterol (Kuo et al. 2010). Fluconazole also
synergistically inhibits Candida albicans when combined
with the calcium channel blocker flunarizine (Liu et al.
2016). Those data suggest the possibility that the BPR-
approved fungicide (benzothiazol-2-ylthio) methyl thiocya-
nate (TCMTB), which also prevents fungal growth by
disrupting ergosterol biosynthesis, could prove more potent
in combination with compounds such as trifluoperazine and
flunarizine. Chemogenomics (Dias et al. 2010) and
Fig. 5 The activity of the combinations IPBC + HEX/TFZ is retained
after coating on glass with sodium alginate. Round glass covers were
coated with 0.25% (w/v) sodium alginate supplemented with 250 μg
ml−1 IPBC, 15 μM HEX, and/or 15 μM TFZ alone or in combination.
Spores of T. virenswere then sprayed on to surfaces of the coated covers.
Images were taken after 14 days. The four replicate images for each
condition are from independent experiments
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proteomics (Santos et al. 2009) studies performed with yeast
indicated that the fungicide mancozebmay cause alterations in
amino acid metabolism and interference with membrane or-
ganisation and embedded transport systems. Given that IPBC
is a carbamate, like mancozeb, it could be hypothesised that
IPBC and dopaminergic drugs such as trifluoperazine target
common processes, e.g., amino acid metabolism or membrane
organisation, potentially explaining certain of the combinato-
rial effects observed in this study.
This study highlights new combinations of BPR-/FDA-ap-
proved compounds that could strongly inhibit the growth of
key environmental fungi, including after incorporation to an
alginate matrix. In combination, the compounds can be de-
ployed at lower concentrations than if used singly, without
impairing overall efficacy, so reducing concerns over chemi-
cal residues and toxicity. As the compounds in each combi-
nation have regulatory approval (at least for certain applica-
tions), this lowers development risk and allows a more rapid
response to help meet the high demand for new biocides. The
study suggests an effective strategy for improving fungicidal
efficacies in biocide applications, using novel compound
combinations.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s00253-021-11211-3.
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